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Abstract
Background:  Integrins are known to be important contributors to cancer progression. We have
previously shown that the integrin β4 subunit is up-regulated in primary colon cancer. Its partner, the
integrin α6 subunit, exists as two different mRNA splice variants, α6A and α6B, that differ in their
cytoplasmic domains but evidence for distinct biological functions of these α6 splice variants is still lacking.
Methods: In this work, we first analyzed the expression of integrin α6A and α6B at the protein and
transcript levels in normal human colonic cells as well as colorectal adenocarcinoma cells from both
primary tumors and established cell lines. Then, using forced expression experiments, we investigated the
effect of α6A and α6B on the regulation of cell proliferation in a colon cancer cell line.
Results: Using variant-specific antibodies, we observed that α6A and α6B are differentially expressed
both within the normal adult colonic epithelium and between normal and diseased colonic tissues.
Proliferative cells located in the lower half of the glands were found to predominantly express α6A, while
the differentiated and quiescent colonocytes in the upper half of the glands and surface epithelium
expressed α6B. A relative decrease of α6B expression was also identified in primary colon tumors and
adenocarcinoma cell lines suggesting that the α6A/α6B ratios may be linked to the proliferative status of
colonic cells. Additional studies in colon cancer cells showed that experimentally restoring the α6A/α6B
balance in favor of α6B caused a decrease in cellular S-phase entry and repressed the activity of c-Myc.
Conclusion: The findings that the α6Bβ4 integrin is expressed in quiescent normal colonic cells and is
significantly down-regulated in colon cancer cells relative to its α6Aβ4 counterpart are consistent with the
anti-proliferative influence and inhibitory effect on c-Myc activity identified for this α6Bβ4 integrin. Taken
together, these findings point out the importance of integrin variant expression in colon cancer cell
biology.
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Background
Integrins are heterodimeric, transmembrane receptors
composed of an α and a β subunit that transmit signals
from extracellular matrix components to the cell interior.
Integrins do not possess intrinsic signalling capacities, but
rather mediate positional information by interacting with
a large range of scaffolding proteins resulting in activation
of several signalling molecules, such as Ras and PI3K,
leading to subsequent activation of, among other mole-
cules, JNK, Jun, Erk and CyclinD [1]. The net result of this
integrin mediated intracellular signalling is control of cel-
lular functions such as proliferation, migration, invasion
and survival, all of which are pivotal events in cancer pro-
gression [2]. The existence of 18 α subunits and 8 β subu-
nits leads to the formation of at least 24 distinct integrins,
which are further diversified by extensive alternative splic-
ing and post-translational modifications [3].
The accumulated findings of an association between high
expression levels of the α6 integrin subunit and carci-
noma cell invasion, metastatic capacity, apoptosis evasion
and negative patient outcome [4-6] strongly argue in favor
of a role for α6 containing integrins in human cancers.
While the α6 subunit can dimerize with either β1 or β4
subunits, it preferentially dimerizes with the β4 subunit.
In fact, in cells that express significant amounts of β4,
such as human intestinal epithelial cells [7], the forma-
tion of α6β1 is nominal. Recent work from our laboratory
has demonstrated an overall up-regulation of the expres-
sion of the β4 integrin subunit in primary tumors of the
human colon [8] strongly supporting the notion that the
α6β4 integrin is an important player in the migration and
invasion of colon cancer cells [4,9]. These observations,
taken together with the reported presence of this major
laminin receptor at the invasive front of colorectal cancers
[10], argue for an important role for the α6β4 integrin in
colon cancer progression [11].
The α6 integrin subunit exists as two distinct variants, α6A
and α6B, that differ in their cytoplasmic domains as the
result of alternative splicing of a single exon [12]. Thus,
the inclusion of an alternatively spliced exon results in the
formation of the α6A variant, while exclusion leads to a
reading frame shift, use of an alternative stop codon and
formation of the α6B variant. These two variants show
dissimilar spatial and temporal patterns of expression in
various human organs and tissues [13,14]. For example,
the α6A variant is exclusive to the mammary gland, basal
keratinocytes and peripheral nerves, while the α6B variant
is strongly favored in the kidney [13]. These distinct
expression patterns, in combination with the conserva-
tion of the two variants in all mammalian species studied,
suggest a biological importance for the existence of both
molecules [3]. These arguments are supported by the
divergent capacities of the α6A and -B subunits to initiate
intracellular biochemical events, namely tyrosine phos-
phorylation of paxillin [15] and activation of the Ras-
MEK-ERK pathway [16]. However, further evidence for
the biological role of these α6 integrin splice variants is
still lacking.
In the present study, we sought to establish the expression
patterns and possible functions of the α6A and α6B
integrin subunits in the normal human and adenocarci-
noma cells of the colon. Our data show that these two var-
iants are differentially expressed according to cell state.
The A variant was predominant in the progenitor cells of
the normal colon while the B variant was predominant in
mature differentiated colonocytes. Significantly, we show
a diminishment of α6B variant expression in primary
colon carcinomas and adenocarcinoma cell lines. Interest-
ingly, forced expression of the α6B variant revealed a spe-
cific ability of this variant to inhibit colonocyte
proliferation and c-Myc activity.
Methods
Tissues
Samples of adult colon were obtained from patients
between the ages of 49 and 86 years undergoing surgical
treatment for colon adenocarcinoma. For each patient,
samples from the primary tumor and from non-diseased
areas (at least 10 cm distant from the lesion) correspond-
ing to the resection margin were obtained. Diagnoses of
adenocarcinoma were confirmed by pathologists. Staging
of the carcinomas was according to Astler and Coller [17].
Resection margins of colon specimens obtained from
patients undergoing surgery for pathologies other than
colon cancer (bowel obstruction, diverticulosis, etc.) were
also used for immunofluorescence. All tissues were
obtained in accordance with protocols approved by the
local Institutional Human Research Review Committee
for the use of human material. The preparation and
embedding of tissues for cryosectioning and RNA extrac-
tion was performed as described previously [18]. Addi-
tional paired samples (resection margin and confirmed
carcinomas) were obtained from the Cooperative Human
Tissue Network (Midwestern Division, Ohio State Univer-
sity, OH) which is funded by the National Cancer Insti-
tute.
Indirect immunofluorescence
Cryosections 3 μm thick were fixed in 2% paraformalde-
hyde (α6A, Ki67 and Rbm19) or -20°C ethanol (α6B).
Nonspecific protein-protein interactions were blocked for
one hour at room temperature by immersion of slides in
10% goat serum (α6A) or 2% BSA (α6B) in PBS followed
by incubation with the primary antibodies diluted 1:200
in their respective blocking solutions overnight at room
temperature. Following extensive washing in PBS, the
slides were incubated with either FITC or rhodamine con-
jugated secondary antibodies raised against mouse and
rabbit IgG (Chemicon), respectively, for one hour at roomBMC Cancer 2009, 9:223 http://www.biomedcentral.com/1471-2407/9/223
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temperature before being washed in PBS. The slides were
stained with Evan's blue (0.01% in PBS) before being
mounted in glycerol:PBS (9:1) containing 0.1% paraphe-
nylenediamine and observed for fluorescence with a Leica
Reichart Polyvar 2 microscope (Leica Canada, Saint-Lau-
rent, QC) equipped with a Leica DFC300 FX digital color
camera. In all cases, no immunofluorescent staining was
observed when a mix of mouse and rabbit non-immune
sera replaced primary antibodies.
Primary antibodies
Two antibodies recognizing integrin α6A (1A10) and α6B
(6B4) [13] were originally generous gifts from Dr. A. Son-
nenberg (Division of Cell Biology, The Netherlands Can-
cer Institute, Amsterdam, The Netherlands).
Subsequently, these antibodies were obtained from
Chemicon (Temecula, CA; 1A10) and MUbio Products
(Maastricht, The Netherlands; 6B4). Mabs 1A10 and 6B4
were used for western blots and co-immunoprecipitation.
For indirect immunofluorescence, 6B4 and a rabbit poly-
clonal α6A (α6-cytoA) [19] antibody was obtained and
employed in place of 1A10. This antibody was a generous
gift from Dr. de Curtis (Department of Molecular Pathol-
ogy and Medicine, San Raffaele Scientific Institute, Milan,
Italy). The anti-Ki67 monoclonal antibody KiS5 and the
polyclonal anti-lysozyme antiserum were from Chemicon
and DAKO Cytomation (Glostrup, Denmark). The anti-
progenitor cell Rbm19 antibody [20] was a kind gift from
Dr. Alan M. Mayer (Department of Pediatrics, Medical
College of Wisconsin, WI). To probe for β-actin, the anti-
body C4 from Chemicon was employed.
Plasmids and plasmid construction
The c-Myc responsive luciferase reporter plasmid, pMyc-
TA-Luc (Clontech, Mountain View, CA), carries six c-Myc
binding sequences in front of the minimal TATA box from
the herpes simplex thymidine kinase (HSV-TK) promoter.
An Rb responsive luciferase reporter plasmid, pRb-TA-Luc
(Clontech) was also used. An expression vector contain-
ing the cDNA of integrin α6A, pRc/CMV-α6A [21], was a
generous gift from Dr. Sonnenberg (Division of Cell Biol-
ogy, The Netherlands Cancer Institute, Amsterdam, The
Netherlands). The α6A cDNA was subcloned into the viral
expression vector pLPCX (BD Bioscience Clontech, Mis-
sissauga, ON) by a non-directional strategy using Hind III.
Correct orientation was verified by restriction enzyme
analysis. cDNA originating from a preparation of fetal epi-
thelial enterocytes separated from the mesenchyme using
Matrisperse (BD Biosciences, Mississauga, ON) as
described previously [22] was used as a template for PCR
amplification of the cytoplasmic tail of the α6B subunit
using Pwo polymerase (Roche, Laval, QC). The upstream
primer (5' TGCTGAAAGAAAATACCAGA 3') spanned an
endogenous XbaI site, while the downstream primer (5'
GC TCTAGAGAAAAAGCAGTTTGGGTACT 3') introduced
another (underlined sequence.) The amplified DNA was
ligated into pPCR-Script (Stratagene, La Jolla, CA) and
verified for fidelity by sequencing. Subsequently, the
cDNA encoding the cytoplasmic tail of the integrin α6A
subunit in pRc/CMV-α6A was replaced by the cDNA
encoding the cytoplasmic tail of the integrin α6B subunit
by XbaI digestion of the recipient (pRc/CMV-α6A) and
donor (pPCR-Script-α6B) vectors followed by ligation,
generating pRc/CMV-α6B. The cDNA encoding the
integrin α6B subunit was subcloned into the pLPCX vec-
tor using the same strategy as for α6A. A mammalian epi-
somal expression vector, pEEP1, was used to generate
populations of Caco-2/15 cells over-expressing the two
integrin α6 splice variants. Integrin α6A or α6B subunit
cDNA was excised from pRc/CMV-α6A and pRc/CMV-
α6B, respectively, using HindIII, Klenow filled and blunt-
end ligated into a Klenow filled NotI site in pEEP1, gener-
ating pEEP1-α6A and pEEP1-α6B.
Cell culture and generation of colon cancer cells over-
expressing α6A and α6B
The colon cancer cell line, Caco-2/15 was grown in
DMEM (GIBCO, Burlington, ON) supplemented with
10% fetal bovine serum (ICN Biomedicals, Aurora, OH),
1% HEPES and 1% Glutamax (both from GIBCO, Burl-
ington, ON) as described previously [23]. The colon can-
cer cell lines HT-29, COLO 201, DLD-1, HCT 116, T84,
SW480 and SW620 were grown in accordance with
instructions provided by the ATCC (Rockville, MD). All
cells were grown in an atmosphere of 95% air and 5%
CO2 at 37°C.
The pEEP1-α6A and pEEP1-α6B plasmids were intro-
duced into 1 × 106 Caco-2/15 cells by nucleofection using
the Amaxa Biosystem Nucleofection kit (ESBE Scientific,
St. Laurent, QC) using the T-20 setting. Immediately fol-
lowing nucleofection, the cells were seeded onto collagen
coated cell culture dishes (Falcon, Franklin Lakes, NJ). 24
hours post-nucleofection the cells were subjected to
hygromycin (Multicell, St. Bruno, QC) selection at a con-
centration of 200 μg/ml for 10 days. This selection pres-
sure was maintained throughout the experimental period
to ensure continuous replication and transfer of the episo-
mal plasmid. Forced expression of the α6A and α6B sub-
units was monitored by western blot.
BrdU incorporation and staining
BrdU incorporation and staining was performed accord-
ing to the manufacturer's (Roche Applied Science, Laval,
QC) instructions. Briefly, 24 hours after plating of cells in
LabTeks (Nalge Nunc, Rochester, NY) the cells were incu-
bated for two hours with normal medium containing
BrdU then immediately subjected to anti-BrdU and DAPI
staining. For each condition, two random fields per well
were counted for DAPI and BrdU positive cells and the
BrdU positive cell population was determined as a per-BMC Cancer 2009, 9:223 http://www.biomedcentral.com/1471-2407/9/223
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centage of total DAPI positive cells. All experiments were
performed in quadruplicate and repeated three times.
Western blot and immunoprecipitation
Western blots were performed as SDS-PAGE under non-
denaturing conditions using 120 μg of whole cell lysate
per lane. After transfer of the separated samples to a nitro-
cellulose membrane (BioRad, Hercules, CA) unspecific
protein binding to the membrane was blocked by 5%
skim milk-powder in PBS-0.1% Tween followed by incu-
bation with the α6A 1A10 monoclonal antibody. Follow-
ing detection, the membrane was stripped of antibody by
incubation in stripping solution (50 mM Tris (pH 6.8),
2% SDS, 100 mM β-mercaptoethanol) at 50°C for 20
minutes after which the membrane was reprobed with the
α6B 6B4 antibody using 2% BSA/0.1% Tween as blocking
solution. Finally, the membrane was restripped and rep-
robed with a β-actin antibody as input control.
For immunoprecipitation of α6β4 and α6β1, newly con-
fluent Caco-2/15 cells and keratinocytes (a kind gift of Dr
L. Germain, LOEX, Université Laval, Québec, QC) were
metabolically labeled using Promix [35S]methionine and
cystine (Amersham Pharmacia Biotech), 200 μCi/ml for 6
h. Cells were lysed and processed as previously described
[7] for immunoprecipitation of α6-containing integrins
with the antibody G0H3 and Protein-G Sepharose (Invit-
rogen). Radioactive samples were analyzed under reduced
and nonreduced conditions by SDS PAGE [7].
RT-PCR
First strand cDNA synthesis was performed with 2 μg total
RNA using oligo(dT)12–18  (Amersham Pharmacia, Bay
d'Urfé, QC) as primer and Omniscript reverse tran-
scriptase (Qiagen, Mississauga, ON) for synthesis. Primers
used to co-amplify the α6A and α6B transcripts using 1/
50 of the synthesized cDNA above were sense: 5'-
CTAACGGAGTCTCACAACTC-3' and antisense: 5'-AGT-
TAAAACTGTAGGTTCG-3'. Each cycle was composed of
template denaturation at 94°C for 1 minute, primer
annealing at 65°C for 1 minute and elongation at 72°C
for 1 minute. The primer annealing temperature was
decreased by 0.5°C after each round of amplification for
40 cycles followed by a final 15 cycles at an annealing
temperature of 45°C.
Real-time quantitative RT-PCR
Quantitative RT-PCR was performed as previously
described)[24]. Three different primer pairs for the
integrin  α6 subunit were tested for amplification effi-
ciency and fidelity. The primer pair termed α6PD-2 was
chosen for amplification of cDNA coding for the integrin
α6 subunit based on a superior amplification efficiency
and lack of primer dimer formation as assessed by melting
curve analysis. The Ct-values were converted into relative
expression values compared to a pooled RNA standard
(QPCR Human Reference Total RNA, Stratagene, La Jolla,
CA) before normalization of α6 expression against a
weighted average of three normalizing genes (B2M, MTR
& MAN1B1) using the geNorm applet [25]. Briefly, this
algorithm normalizes a gene of interest against several
normalizing genes, rather than against a single gene, thus
obtaining an analysis of expression that is less likely to be
impacted by any random fluctuations in the expression
level of the normalizing gene(s). The sequences of the
α6PD-2 primer were: sense 5' TGGGATATGCCTCCAG-
GTT 3', antisense 5' TGTAGCCACAGGGTTTCCTC 3'.
Primer pairs for B2M, MAN1B1, and MTR have been
described previously)[24]. The annealing temperatures of
the reactions were 57°C (α6) or 58°C (B2M, MAN1B1
and MTR) and the amplification efficiencies of the reac-
tions were 100.7%, 105.7%, 98.9% and 96.8% for α6,
B2M, MTR and MAN1B1, respectively, as determined by
standard curve analysis.
Transfection and luciferase measurement
Equal numbers of Caco-2/15 cells were seeded in 24-well
plates (Falcon, Franklin Lakes, NJ) and grown to 40–60%
confluence before being transiently transfected in serum-
free medium using FuGENE transfection agent (Roche,
Indianapolis, IN) in a μg DNA to μl transfection agent
ratio of 1:9. Cells were kept under normal growth condi-
tions after transfection and harvested for analysis 48
hours post-transfection. All transfections were performed
as co-transfections using a renilla luciferase expression
plasmid to establish an internal control for transfection
efficiency; thus allowing for normalization of cell number
and viability. Promoter activities of the various reporter
plasmids were expressed using the arbitrary unit "RLU"
(relative luciferase units). Numeric values of CMV pro-
moters in control transfections (empty vector) were kept
equal to experimental (α6A and α6B) numeric values by
adjusting the absolute level of plasmid as measured by μg.
DNA concentrations in transfections were kept constant
with the addition of pBluescript SK+ (Stratagene, Cedar
Creek, TX). Equal amounts (25 ng) of reporter plasmid
and expression vector (pRc/CMV-α6A and pRc/CMV-
α6B) were cotransfected with 2 ng of pCMV-Renilla per
well. Firefly and renilla luciferase activity was measured
using the Dual-Luciferase®  Reporter Assay System
(Promega Corporation, Madison, WI) according to the
manufacturer's instructions using an Orion microplate
luminometer from Berthold (Montreal Biotech, Kirkland,
QC) for detection of the chemiluminescent signal. Indi-
vidual experimental results were normalized to the aver-
age of the RLU of the empty vector cotransfectant in the
corresponding experiment.
Results
Expression of α6 subunit variants in the normal colon
We previously showed the ubiquitous presence of the α6
dimerization partner β4 along the glandular unit of theBMC Cancer 2009, 9:223 http://www.biomedcentral.com/1471-2407/9/223
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Representative immunofluorescent staining of frozen serial sections of the adult colonic mucosa for the detection of the α6A  and α6B splice variants and proliferation markers Figure 1
Representative immunofluorescent staining of frozen serial sections of the adult colonic mucosa for the detec-
tion of the α6A and α6B splice variants and proliferation markers. (A) Expression of the A variant showing a predom-
inant distribution in the lower half of the glands (g), the region containing the progenitor cells as confirmed by 
immunodetection with Ki67 (B) and Rbm19 (C). (D, E) The B variant was detected in the upper half of the glands and at the 
surface (s) epithelium. (F-I) Higher magnification of the lower gland region stained for the detection of α6B (F), α6A (G), Ki67 
(H) and Rbm19 (I) showed that in the colon, α6B is absent from the lower crypt while both α6A and the proliferative zone 
extend to the bottom of the glands. Red-brown signal: Evan's blue counter stain. Magnifications: A-D: scale bars in A and D = 
50 μm; E-I: scale bar in E = 25 μm.BMC Cancer 2009, 9:223 http://www.biomedcentral.com/1471-2407/9/223
Page 6 of 13
(page number not for citation purposes)
human colon [8]. We, therefore, proceeded directly to
delineate the specific expression patterns of the α6A and
α6B splice variants in the normal human adult colonic
mucosa (Figure 1). The α6A subunit was expressed in the
basal membrane of epithelial cells concentrated in the
lower half of the glands (Figure 1A), a region that contains
the progenitor cells as identified by co-immunodetection
with the proliferative antigens Ki67 and Rbm19 (Figure
1B, C, G, H, I). Staining for the α6B subunit on serial sec-
tions revealed its presence in the epithelium located in the
upper half of the glands and at the base of the surface epi-
thelium (Figure 1D, E), while it was not detected in the
lower crypt (Figure 1F). The association of α6A with the
actively growing cell population and α6B with the mature
differentiated population supports the hypothesis that
each variant possesses a specific distinct function, neces-
sary for intestinal homeostasis.
α6 is up-regulated in colon cancer cells and undergoes a 
shift away from the α6B variant
The α6β4 integrin is frequently up-regulated in several
cancer types [2]. As in our previous study on the β4 subu-
nit [8], using quantitative PCR we observed a significant
up-regulation of total α6 expression in paired primary
tumor samples versus patient matched normal resection
margins (RM) (Figure 2A). We then assessed whether
modulation of α6 splice-variant expression accompanied
the overall up-regulation of total α6 in primary tumors.
Competitive RT-PCR using primers that amplify the tran-
scripts of both α6 variants showed an overall dominance
of α6B expression in the healthy resection margins (Figure
2B – RM). Furthermore, a clear down-regulation of expres-
sion of the α6B variant in conjunction with a possible
increase in the α6A variant were observed in patient
matched tumors (Figure 2B, C). Overall, 81% of the 21
Integrin α6 is up-regulated in colon cancer cells and undergoes a shift towards the α6A variant Figure 2
Integrin α6 is up-regulated in colon cancer cells and undergoes a shift towards the α6A variant. (A) Quantitative 
RT-PCR of total α6 subunit mRNA in patient matched resection margins (RM) and corresponding primary tumors (Tu). Mean 
± SEM. *: p = 0.025, n = 21, paired t-test. Representative competitive RT-PCR of the α6A and α6B variants (B) and (C) ratio of 
α6B/α6A transcript levels in patient matched RM and primary tumors of the human colon. Mean ± SEM. *: p = 0.05, n = 21, 
paired t-test. (D) Dot graphs of the individual α6B/α6A ratios showing a sharp decrease in 17 (grey) of the 21 paired samples 
analyzed.BMC Cancer 2009, 9:223 http://www.biomedcentral.com/1471-2407/9/223
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pairs showed the same change in expression in the tumor
sample, resulting in a statistically significant shift towards
a diminished α6B/A-ratio in primary cancers compared to
healthy resection margins (Figure 2D). However, no cor-
relation was noted between tumor grade or stage and α6B
down-regulation (data not shown). A predominant
expression of the α6B variant in normal colonic tissue is
in accordance with the fact that the quiescent cell popula-
tion outsizes the proliferative cell population in the nor-
mal colon. Correspondingly, a shift towards higher
expression of the A variant in hyperproliferative colon car-
cinomas correlated with the association of this variant
with the proliferative compartment of the healthy colon.
The patterns of expression of α6A and α6B were analyzed
in situ by indirect immunofluorescence on 8 primary
tumors and their corresponding resection margins (Figure
3). All specimens were well- to moderately-differentiated
tumors. In all examined resection margins the differential
distribution of α6A in the lower half of the gland and α6B
in the upper half of the gland and in the surface epithe-
lium was comparable to that observed in normal colon
specimens (data not shown). Analyses of frozen serial sec-
tions from primary tumors revealed that the A variant was
now found almost ubiquitously expressed at the base of
carcinoma cells (Figure 3A, C, E, and 3G) while the B var-
iant was detected in most, but not all, corresponding
regions (Figure 3B, D, F and 3H). These results exposed
the widespread overlap of expression between the two α6
variants in colon cancer epithelia suggesting the loss of
segregated expression found in normal colon tissue. In
addition, extensive expression of α6A in carcinoma cells
was consistent with the observed up-regulation of α6A at
the transcript level (Figure 2B, D).
We next investigated the relative α6A and α6B levels in 6
well established colon cancer cell lines to see if this char-
acteristic was conserved. All six cell lines tested predomi-
Expression of α6A and α6B integrin subunits in colon cancer specimens Figure 3
Expression of α6A and α6B integrin subunits in colon cancer specimens. Representative images by indirect immun-
ofluorescence staining of α6A (A, C, E and G) and α6B (B, D, F and H) integrin subunits in serial sections of colon cancer spec-
imens (A, B; C, D; E, F and G, H) showing the loss of variant segregation, leading to widespread overlap of both variants 
(arrows). Some regions, however, displayed the expression of only one variant, with no expression of the other (arrowheads). 
Red-brown signal: Evan's blue counter stain. Magnifications: scale bars = 50 μm.BMC Cancer 2009, 9:223 http://www.biomedcentral.com/1471-2407/9/223
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nantly expressed the A-variant (Figure 4A). However, at
least one exception to this exists since the Colo 320 cell
line has been previously shown to predominantly express
the B-variant [13] suggesting that, as observed herein for
the primary tumors where 4 out of the 21 pairs analyzed
did not show an α6A subunit increase (Figure 2D), the
relation between high α6A expression and a pro-prolifer-
ative state is not absolute in colon cancer cell lines of
human origin although quite frequent. To further investi-
gate the phenomenon, we used the two colon cancer cell
lines, Caco-2/15 and HT-29 that share the trait of under-
going a differentiation program, characterized by a signif-
icant decline in proliferation, as a consequence of culture
method. These two cell types express both β1 and β4 sub-
units but because the affinity of α6 for β4 is much greater
than for β1, it can be assumed based on studies performed
on keratinocytes and other cell types that the α6A/B vari-
ants mainly combine with β4 [7,13,26]. This was con-
firmed by immunoprecipitating the α6B complex from
metabolically labeled Caco-2/15 or primary keratinocytes
Analysis of α6A and α6B integrin subunits in colon cancer cell models Figure 4
Analysis of α6A and α6B integrin subunits in colon cancer cell models. (A) Representative competitive RT-PCR of 
the α6A and α6B variants in six colon cancer cell lines. (B) Immunoprecipitation of the α6 subunits using the G0H3 antibody 
from metabolically labeled Caco-2/15 cells and keratinocytes and analyzed on SDS-PAGE under nonreduced (NR) and reduced 
(R) conditions showing that α6 predominantly associates with the β4 subunit in these cells. Apparent molecular weights are 
indicated on the left side. The dots indicate the expected sites of β1 subunit migration under both NR and R conditions. (C) 
Further analysis by competitive RT-PCR for splice variant expression of two intestinal cell lines at different differentiation 
stages showing up-regulation of the α6B variant upon cell-cycle exit. Caco-2/15: proliferative at sub-confluence (SC) while 
becoming non-proliferative at post-confluence (PC); HT-29: grown under non-permissive (Glu: glucose) or permissive (Ino: 
inosine) conditions for differentiation and cell cycle exit. (D, E) The α6A/α6B ratio of transcript (D) and protein (E) levels rel-
ative to differentiation of the various intestinal cells. Means ± SEM, n = 3–6. *, **: Statistically significantly different with p < 0.05 
and 0.01, respectively, from subconfluent Caco-2/15. Tukey's One Way Analysis of Variance (ANOVA).BMC Cancer 2009, 9:223 http://www.biomedcentral.com/1471-2407/9/223
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with [35S] methionine and cystine using the α6 subunit-
specific G0H3 antibody and analysis by SDS-PAGE under
reduced and non-reduced conditions. As shown in Figure
4B, both keratinocytes and Caco-2/15 cells display bands
at approximately 205 kD and 150 kD and 205 kD and 120
kD corresponding to the β4 and α6 subunits under non-
reduced and reduced conditions, respectively. The β1 sub-
unit remained below detection level in Caco-2/15 cells
confirming that α6 predominantly associates with β4 in
intestinal cells. We thus used the two intestinal cell mod-
els Caco-2/15 and HT-29 to monitor the expression of the
α6A and B variants during the course of proliferation
arrest accompanied by the induction of differentiation.
Competitive RT-PCR revealed that the ratio of α6A to α6B
was altered as a function of cell state, reflecting the situa-
tion in vivo. Higher levels of α6A were associated with
actively growing cells and a subsequent switch in favour of
α6B was found to be associated with cells that had under-
gone cell cycle arrest (Figure 4C, D). This trend was mir-
rored in protein levels as well when detected with variant
specific antibodies (Figure 3E).
α6B inhibits proliferation in colon cancer cells
Elevated levels of unligated integrins can provoke intrac-
ellular signalling resulting in apoptosis [27]. Conse-
quently, we focused our experiments on the well-
characterized colon cancer cell line Caco-2/15 which has
the ability to constitutively deposit significant amounts of
laminins [28], the α6β4 ligands. To evaluate the hypothe-
sis that an altered α6A/α6B ratio could be of functional
importance for the proliferative status of colon cancer
cells we attempted to create stable cell lines over-express-
ing α6A and α6B. However, we were repeatedly unable to
maintain the α6B cells in long term cultures suggesting
that over-expression of the α6B variant impaired cell pro-
liferation. We were unable to perform complementary
studies using RNAi since the only difference between the
mRNA of the α6A and α6B variants is the inclusion of an
alternatively spliced exon in the α6A transcript. As no
region of the transcript is unique to the α6B variant it was
not possible to exclusively target the α6B transcript for
RNAi.
We consequently opted to perform studies on nucleo-
fected cell populations over-expressing the two variants
despite the difficulty in maintaining the α6B over-express-
ing cells, analyzing the cells shortly following the 10-day
antibiotic selection period ensuring that all cells expressed
their respective episomal vectors (Figure 5A). Prolifera-
tion was assessed using BrdU incorporation assays. With
this strategy we consistently observed that the proportion
of  α6B transfectants entering S-phase was significantly
diminished compared to the α6A transfectants and the
empty vector control (Figure 5B), suggesting that predom-
inant expression of the α6B subunit inhibits S-phase entry
in intestinal epithelial cells in accordance with the pre-
dominant expression of this subunit in the non-prolifera-
tive compartment of the colon and it's relative down-
regulation in colon carcinomas. Consistent with these
observations, a specific reduction in transcriptional Rb
activity was observed in luciferase assays (Figure 6A) sup-
porting the observation that the α6B-expressing cells are
exiting cell cycle in G1 [29].
α6B inhibits c-Myc activity in colon cancer cells
Colon cancer cells and glandular proliferative cells require
the activity of the proto-oncogene c-Myc for proliferation
[30]. We next evaluated the ability of the α6B subunit to
modulate c-Myc activity by performing co-transfections of
the two integrin α6 variants with a luciferase reporter plas-
mid responding to c-Myc activity (pMyc-Ta-Luc). Experi-
ments performed in colon cancer cells (Caco-2/15)
demonstrated that pMyc-TA-luc activity was significantly
down-regulated by α6B over-expression (Figure 6B), but
Forced expression of the α6B subunit inhibits intestinal cell  proliferation Figure 5
Forced expression of the α6B subunit inhibits intesti-
nal cell proliferation. (A) Forced expression of the α6A 
and α6B integrin subunits was confirmed by western blot. (B) 
Quantification of Caco-2/15 cells undergoing S phase entry 
expressing α6A and α6B vs an empty vector control was 
assessed by BrdU incorporation. Mean ± SD. *: Statistically 
significantly different from the A variant, p < 0.01, Tukey's 
One Way Analysis of Variance (ANOVA).BMC Cancer 2009, 9:223 http://www.biomedcentral.com/1471-2407/9/223
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was not altered by α6A. The decrease in c-Myc activity in
the α6B co-transfections was not due to any changes in c-
Myc protein levels as determined by western blot analyses
(Fig 6C).
Discussion
The functional importance of the instructive interactions
between the epithelial cell compartment with the sur-
rounding extracellular milieu has long been recognized in
the intestinal tract [31,32]. Our observations that the α6A
and α6B splice variants are differentially expressed in pro-
genitor and mature cells of the colonic epithelium,
located in the lower and upper half of the glands respec-
tively [33], are consistent with previous findings showing
the existence of distinct microenvironments between the
proliferative and differentiation compartments in the gut
[7,34]. More importantly, it suggests that the intrinsic role
of each α6 variant is distinct. In this context, our finding
that the α6B variant exclusively repressed proliferation
concurs with its low level of expression in the proliferative
zone and its predominance in the non-proliferative com-
partments of the colon as shown herein, as well as in the
small intestine [35]. The effect of the α6B variant on cell
proliferation in vitro appeared sufficient to prevent expan-
sion of these cultures although the potential low grade
contribution of apoptosis or autophagy cannot be
excluded at the present time.
Colon cancer is the third leading cause of cancer related
mortality in the United States [36]. The occurrence and
development of most colon cancers follows a stereotypi-
cal pattern of a progressive accumulation of gain- and loss
of function mutations of oncogenes and tumor suppres-
sor genes [37]. It is also clear that neoplastic cells tend to
up-regulate the expression of integrins favoring their
migration, survival and proliferation during the complex
Response of Rb and c-Myc promoter activities in Caco-2/15 cells Figure 6
Response of Rb and c-Myc promoter activities in Caco-2/15 cells. (A) Rb activity was determined with an Rb-TA-Luc 
responsive promoter in the presence of forced α6A or α6B expression. (B) c-Myc activity was determined with a Myc-TA-luc 
responsive promoter. Left: Effect of forced c-Myc expression on the myc-responsive promoter. Right: Effect of forced α6A or 
α6B expression on the myc-responsive promoter. Mean ± SEM. ***: statistically significantly different from empty vector (EV), 
p < 0.001, Tukey's One Way Analysis of Variance (ANOVA). (C) Representative western blot for c-Myc expression in Caco-2/
15 cells stably expressing the α6A and α6B integrin subunit or EV as in Figure 5.BMC Cancer 2009, 9:223 http://www.biomedcentral.com/1471-2407/9/223
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multistep generation of tumors [2]. The mechanistic and
biochemical roles of the α6β4 integrin in carcinoma biol-
ogy are well documented[4,38]. Our results describe
novel aspects of the biology of the α6β4 integrin variants
in colon cancer. Thus, after having identified that distinct
forms of the integrin β4 subunit were expressed in normal
intestinal proliferative vs cancer cells [8], we observed
herein a shift in α6 variant expression from a predomi-
nantly high α6B/α6A ratio in the normal colon to a pre-
dominantly low α6B/α6A ratio in primary tumors.
c-Myc is a key player in cancer formation and progression
due to the numerous roles it plays in proliferation control
and apoptosis [39]. Indeed, c-Myc expression has been
demonstrated to be up-regulated in 70% of colon cancers
[40] and its well documented effects include stimulation
of cyclinD expression, inhibition of p21cip1 and p27kip1
expression and inactivation of Rb, leading to enhanced G1
to S-phase transition [39]. Given the central role of c-Myc
in the control of critical cellular events, its transcriptional
functions are tightly regulated by several molecular path-
ways [41]. Prototypically, the control of cellular c-Myc lev-
els are largely attributed to the canonical activity of the
Wnt-pathway [42]. However, the activity and expression
levels of c-Myc are regulated by several other molecular
mechanisms including distinct signalling pathways and
interaction with binding partners [39,43]. For instance,
the nucleoshuttling scaffold protein bridging integrator-1
(Bin1) has been shown to strongly inhibit c-Myc tran-
scriptional activity in a Wnt-pathway independent man-
ner [44,45]. Interestingly, Bin1 can selectively interact
with the cytoplasmic domain of the α6B integrin subunit
in yeast two-hybrid studies [46] and its expression has
been reported to be associated with the non-proliferative
cell population in the normal intestine [47] suggesting a
possible mechanism for the inhibitory effect of α6Bβ4 on
c-Myc activity.
While there is substantial evidence for the differential
capacity of the α6Aβ1 and α6Bβ1 integrins to initiate
intracellular signalling [15,16] and facilitate migration on
laminin [15], these studies have all found that the α6Aβ1
integrin functions as the "active" integrin, whereas the
α6Bβ1 integrin appears to have no major active role in
these events [15,16,48-50]. In this context it is noteworthy
that over-expression of the α6A variant in colon cancer
cells did not stimulate proliferation as compared to the
control cells, but rather the α6B variant actively inhibited
proliferation and c-Myc activity, under conditions where
integrin/ligand interactions occurred. It is furthermore
noteworthy that the α6A/B splice variants can dimerize
with both the β1 and the β4 subunits to form two distinct
functional integrins, α6β1 and α6β4, but that the α6 sub-
unit preferentially dimerizes with the β4 subunit
[7,13,26], as confirmed herein. Thus, the specific ability of
the α6B subunit to inhibit proliferation, in accordance
with its predominant expression in the quiescent com-
partment of the normal colon and its down-regulation in
primary colon cancers and adenocarcinoma cell lines,
strongly suggests that the expression and ratio of the α6A
and α6B splice variants are inherent to normal intestinal
homeostasis and exploited by colon cancer cells.
Conclusion
In this study, we provide the first functional evidence that
the α6Bβ4 integrin can exert distinct biological functions
compared to its α6Aβ4 counterpart. Analyzing the expres-
sion of the two α6 variants in the human normal colon
led to the discovery that the A and the B variants are dif-
ferentially expressed in proliferative and differentiated
cells, respectively. More significantly, a net shift toward a
predominant A variant expression was observed in pri-
mary colorectal tumors and in adenocarcinoma cell lines
suggesting that a high α6A/B ratio is required for both
normal and cancer cell proliferation. To test this hypothe-
sis, we forced α6A and α6B expression and found that re-
establishing predominant α6B subunit expression inhib-
ited colon cancer cell proliferation and c-Myc activity.
Taken together, these findings point out the importance
of integrin variant expression in colon cancer cell biology.
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